harvey al. natural products in drug discovery. 2008...
TRANSCRIPT
Bibliography
173 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
BIBLIOGRAPHY
1. Harvey AL. Natural products in drug discovery. Drug Discovery Today, 2008,
13(19-20), 894-901.
2. Patwardhan B, Vaidya ADB, Chorghade M, Joshi SP. Reverse pharmacology
and systems approaches for Drug Discovery and Development, Current
Bioactive Compounds, 2008, 4(4), 1-12.
3. Patil D, Gautam M, Mishra S, Jadhav U, Suresh K, Gairola S, Jadhav SS,
Patwardhan B. Physicochemical stability and biological activity of Withania
somnifera extract on real time and accelerated storage conditions. Planta
Medica, 2010, 76, 481-488.
4. Chitalange SS, Kulkarni PS, Patil D, Patwardhan B, Nanda RK. High
performance liquid chromatographic fingerprint for quality control of
Terminalia arjuna containing Ayurvedic churna formulations. Journal of the
Association of Official Analytical Chemists, 2009, 92, 1016-20.
5. Warude D, Patwardhan, B. Botanicals: quality and regulatory issues. Journal
of Scientific and Industrial Research, 2005, 64, 83-92.
6. World Health Organization, Quality control methods for medicinal plant
materials Revised Draft Update, 1998, 1-49.
7. Saraf SA. Applications of novel drug delivery system for herbal formulations.
Fitoterapia, 2010, 81, 680-689.
8. Yaohua Hu, Peng J, Shuping W, Shikai Y, Xiang Li, Weidong Z, Runhui Liu.
Plasma pharmacochemistry based approach to screening potential bioactive
components in Huang-Lian-Jie-Du-Tang using high performance liquid
chromatography coupled with mass spectrometric detection. Journal of
Ethnopharmacology, 2012, 141, 728-735.
9. Yonghai L, Xi Zhang, Xu Liang, Xinru Liu, Weixing Dai, Shikai Yan,
Weidong Zhanga. Characterization of the constituents in rat biological fluids
after oral administration of Fufang Danshen tablets by ultra-performance
liquid chromatography/quadrupole time-of-flight mass spectrometry. Journal
of Pharmaceutical and Biomedical Analysis, 2010, 52,155-159.
10. Khalid H, Zhari I, Amirin S, Pazillah I. Bioactive Markers Based
Pharmacokinetic Evaluation of Extracts of a Traditional Medicinal Plant,
Piper sarmentosum. Evidence-Based Complementary and Alternative
Medicine, 2011, 1-7.
Bibliography
174 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
11. Sharma S, Thawani V, Hingorani L, Shrivastava M, Bhate VR, Khiyani R.
Pharmacokinetic study of 11-Keto beta-Boswellic acid. Phytomedicine, 2004,
11(2-3), 255-60.
12. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM,
Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP. Pharmacodynamic and
pharmacokinetic study of oral Curcuma extract in patients with colorectal
cancer. Clinical Cancer Research, 2001, 7, 1894-900.
13. Ploeger B, Mensinga T, Sips A, Meulenbelt J, DeJongh J. A human
physiologically-based model for glycyrrhzic acid, a compound subject to
presystemic metabolism and enterohepatic cycling. Pharmaceutical Research,
2000, 17, 1516–1525.
14. The top 10 causes of death. Geneva, Switzerland: World Health Organization;
2008 (Fact sheet 310).
(http://www.who.int/mediacentre/factsheets/fs310_2008.pdf).
15. Paez KA, Zhao L, Hwang W. Rising out-of-pocket spending for chronic
conditions: a ten-year trend. Health Aff (Millwood), 2009, 28, 15-25.
16. Anonymous. Tackling the burden of chronic diseases in the USA. Lancet,
2009, 373, 185.
17. Patel V, Chatterji S, Chisholm D, Ebrahim S, Gopalakrishna G, Mathers C,
Mohan V, Prabhakaran D, Ravindran RD, Reddy KS. Chronic diseases and
injuries in India. Lancet, 2011, 377, 413-428.
18. Tiwari AK, Rao JM. Diabetes mellitus and multiple therapeutic approaches of
phytochemicals: Present status and future prospects. Current Science, 2002,
83, 30-38.
19. Abebe W. Herbal medication: potential for adverse interactions with
analgesic drugs. Journal of Clinical Pharmacy and Therapeutics, 2002, 27,
391-401.
20. Zhou S, Zhou W, Li C, Chen X, Yu X, Xue C, Herington A. Identification of
drugs that interacts with herbs in drug development. Drug Discovery Today,
2007, 12, 664-673.
21. Zhu R, Hu L, Li H, Su J, Cao Z, Zhang W. Novel Natural Inhibitors of
CYP1A2 identified by in silico and in vitro Screening. International Journal
of Molecular Science, 2011, 12, 3250-3262.
Bibliography
175 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
22. Guidance for industry: drug interaction studies-study design, data analysis,
and implications for dosing and labeling.2012.
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guida
nces/default.htm
23. Hu Z., Yang X, Ho PC, Chan SY, Heng PW, Chan E, Duan W, Koh HL, Zhou
S. Herb-drug interactions: a literature review. Drugs, 2005, 65, 1239-1282.
24. Iwata H, Tezukay Y, Usia T, Kadota S, Hiratsuka A, Watabe, T. Inhibition of
human liver microsomal CYP3A4 and CYP2D6 by extracts from 78 herbal
medicines Journal of Traditional Medicine, 2004, 21, 41-50.
25. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed
drugs: a systematic review. Drugs, 2001, 61, 2163-2175.
26. Indian Pharmacopoeia, Indian Pharmacopoeia commission, Ghaziabad, 2007,
2036-2037.
27. Shanmugasundaram KR, Panneezselvam C. The insulinotropic activity of
Gymnema sylvestre an Indian medical herb used in controlling Diabetes
Mellitus. Pharmacological Research Communications, 1981, 13(5), 475-486.
28. Rachh PR, Rachh MR, Ghadiya NR, Modi DC, Patel NM, Rupareliya MT.
Antihyperlipidimic activity of Gymnema sylvestre leaf extract on rats fed with
high cholesterol diet. International Journal of Pharmacology, 2010, 6(2), 138-
141.
29. Chodisetti B, Rao K, Giri A. Phytochemical analysis of Gymnema sylvestre
and evaluation of its antimicrobial activity. Natural Product Research, 2012,
DOI: 10.1080/14786419.2012.676548.
30. Kang MH, Lee MS, Choi MK, Min KS, Shibamoto T. Hypoglycemic activity
of Gymnema sylvestre extracts on oxidative stress and antioxidant status in
diabetic rats. Journal of Agricultural Food Chemistry, 2012, 60 (10), 2517-24.
31. Saneja A, Sharma C, Aneja KR, Pahwa R. Gymnema sylvestre (Gurmar): A
review. Der Pharmacia Lettre, 2010, 2(1), 275-284.
32. Srikanth AV, Sayeeda M, Lakshmi NM, Ravikumar P, Madhava RB.
Anticancer activity of Gymnema sylvestre R.Br. International Journal of
Pharmaceutical Sciences & Nanotechechnology, 2010, 3(1), 897-899.
33. Kanetkar P, Singhal R, Kamat M. Gymnema sylvestre: A memoir. Journal of
Clinical Biochemistry & Nutrition, 2007, 41(2), 77-81.
Bibliography
176 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
34. Shanmugasundaran ERB, Rajeswari G, Baskaran K, Kumar BRR,
Shanmugasundaram KR, Ahmath BK. Use of Gymnema sylvestre leaf extract
in the control of blood glucose in insulin dependent diabetes mellitus. Journal
of Ethnopharmacology, 1990, 30, 281-294.
35. Yoshikaua K, Alimotoa K, Ariharaa S, Natsuura K. Structure studies of new
antisweet constituents from Gymnema sylvestre. Tetrahedron Letters, 1989,
30, 1103-1106.
36. Trivedi PD, Pundarikakshudu K, Shah KA. Validated reverse phase liquid
chromatographic method for quantification of gymnemagenin in the Gymnema
sylvestre R. Br. leaf samples, extract and market formulation. International
Journal of Applied Sciences & Engineering, 2011, 9, 25-31.
37. Toshiaki I, Yamamoto FM, Akiko M, Hiroyuki H. High-performance liquid
chromatography-atmospheric pressure ionization mass spectrometry of
gymnemic acids, Journal of Chromatography, 1991, 557, 383-389.
38. Toshihiro Y, Kenzi M, Kenzo O, Osamu T. Quantitative analysis of
gymnemic acids by high performance liquid chromatography. Nippon
Shokuhin Kagaku Kaishi, 1994, 41, 202- 205.
39. Valivarthi SRR, Kannababu S, Gottumukkala VS. Standardisation of
Gymnema sylvestre R.Br. by high-performance thin-layer chromatography: an
improved method. Phytochemical Analysis., 2006, 17, 192-196.
40. Hamed AI, Janda B, Mahalel UA, Stochmal A, Oleszek W. Profiles of
steroidal saponins from the aerial parts of Tribulus pentandrus,
T.megistopterus subsp. pterocarpus and T. parvispinus by LC–ESI–MS/MS.
Phytochemical Analysis, 2012 DOI: 10.1002/pca.2363.
41. Patil D, Gautam M, Mishra S, Jadhav U, Suresh K, Gairola S, Jadhav SS,
Patwardhan B. Physicochemical stability and biological activity of Withania
somnifera extract on real time and accelerated storage conditions. Planta
Medica, 2010, 76, 481-488.
42. Patil D, Mishra S, Gautam M, Kulkarni P, Suresh K, Gairola S, Jadhav SS,
Patwardhan B. Estimation of protoberberine alkaloids in Tinospora cordifolia
stem crude powder, processed extracts and marketed formulations using
HPLC-DAD method. Chromatographia, 2010, 71, 341-345.
Bibliography
177 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
43. Saller R, Reichling J, Phytotherapie. In: Melchart D., Brenke R., Dobos G.
Gaisbauer M., Saller R. (Eds.), Naturheilverfahren. SchattauerGmbH,
Stuttgart, 2002, 180-293.
44. . R.Bauer, Drug Inform Journal, 1998, 32, 101-110.
45. N.J.Lazarowych, P.Pekos. Drug Inform Journal, 1998, 32, 497-512.
46. Guidance for Industry on Botanical Drug Products, U.S. Department of
Health and Human Services Food and Drug Administration, Center for Drug
Evaluation& Research (CDER). 2004, 33. Available at
www.fda.gov/cder/guidance/index.htm Assessed on 10. May 2009.
47. EMEA Reflection paper on stability testing of herbal medicinal products and
traditional herbal medicinal products (EMEA/HMPC/3626/2009). 2009, 1-3.
48. World Health Organization. Quality control guidelines for medicinal plant
material. 1998, 111.
49. Zhang H, Sun Y, Duan M, Chen Y, Zhong D, Zhang H. Separation and
identification of Aconitum alkaloids and their metabolites in human urine.
Toxicology, 2005, 46, 500-506.
50. Felgines C, Talavera S, Texier O, Gil-Izquierdo A, Lamaison JL, Remesy C.
Blackberry anthocyanins are mainly recovered from urine as methylated and
glucuronidated conjugates in humans. Journal of Agricultural Food
Chemistry, 2005, 53 (20), 7721-7.
51. Naik H, Murry DJ, Kirsch LE. Fleckenstein L. Development and validation
of a high-performance liquid chromatography-mass spectroscopy assay for
determination of artesunate and dihydroartemisinin in human plasma. Journal
of Chromatography B: Analytical Technologies in the Biomedical Life
Sciences, 2005, 25, 816, 233-42.
52. Collett A, Tanianis-Hughes J, Carlson GL, Harwood MD, Warhurst G.
Comparison of P-glycoprotein-mediated drug-digoxin interactions in Caco-2
with human and rodent intestine: relevance to in vivo prediction. European
Journal of Pharmaceutical Sciences, 2005, 26, 386-393.
53. Liang Y, Xie P, Chan K. Quality control of herbal medicines. Journal of
Chromatography B, 2004, 812, 53-70.
54. Xing J, Xie C, Lou H. Recent applications of liquid chromatography–mass
spectrometry in natural products bioanalysis. Journal of Pharmaceutical and
Biomedical Analysis, 2007, 44, 368-378.
Bibliography
178 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
55. Guo J, Xu Q, Chen T. Quantitative determination of astilbin in rabbit plasma
by liquid chromatography. Journal of Chromatography B, 2004, 805, 357-
360.
56. Feras IK, Melpomeni I, Bounartzi, Ioannis N. A validated HPLC
determination of the flavone aglycone diosmetin in human plasma. Biomedical
Chromatography, 2004, 18(10), 800-804.
57. Abe E, Lemaire-HAS, Duverneuil C, Etting I, Guillot E, de Mazancourt P,
Alvarez JC. A novel LC-ESI-MS-MS method for sensitive quantification of
colchicine in human plasma: application to two case reports. Journal of
Analytical Toxicology, 2006, 30 (3), 210-5.
58. Wang S, Wang G, Li X, Sun J, Ma R, Sheng L. Simultaneous determination of
oxymatrine and its active metabolite matrine in dog plasma by liquid
chromatography-mass spectrometry and its application to pharmacokinetic
studies. Journal of Chromatography B, 2005, 817, 319-325.
59. Hao XH, Cheng G, Sun J, Zou MJ, Yu J, Zhang S, Cui FD. Validation of an
HPLC method for the determination of scutellarin in rat plasma and its
pharmacokinetics. Journal of Pharmaceutical and Biomedical Analysis,
2005, 38, 360-363,
60. Qian T, Jiang ZH, Cai Z. High-performance liquid chromatography coupled
with tandem mass spectrometry applied for metabolic study of ginsenoside
Rb1 on rat. Analytical Biochemistry, 2006, 352, 87–96.
61. Molavi A, Shayeganpour V, Somayaji S, Hamdy DR, Brocks A, Lavasanifar
GS, Samuel KJ. Development of a sensitive and specific liquid
chromatography/mass spectrometry method for the quantification of
cucurbitacin I (JSI-124) in rat plasma. Journal of Pharmacy &
Pharmaceutical Sciences, 2006, 9, 158-164.
62. Cai Z, Sinhababu AK, Harrelson S. Simultaneous quantitative cassette
analysis of drugs and detection of their metabolites by high performance liquid
chromatography/ion trap mass spectrometry. Rapid Commun Mass Spectrom,
2000, 14(18), 1637-43.
63. Cai Z, Qian T, Wong RNS, Jiang Z. Liquid chromatography-electrospray
ionization mass spectrometry for metabolism and pharmacokinetic studies of
ginsenoside Rg3. Analytica Chimica Acta, 2003, 492, 283-293.
Bibliography
179 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
64. Li HL, Zhang W, Zhang C, Liu RH Wang, XW, Wang XL, Zhu JB, Chen
CL. Bioavailabilty and pharmacokinetics of four active alkaloids of traditional
Chinese medicine Yanhuanglian in rats following intravenous and oral
administration. Journal of Pharmaceutical and Biomedical Analysis, 2006, 41,
1342–1346.
65. Tong L, Zhou D, Gao J, Zhu Y, Sun H, Bi K. Simultaneous determination of
naringin, hesperidin, neohesperidin, naringenin and hesperetin of Fractus
aurantii extract in rat plasma by liquid chromatography tandem mass
spectrometry, Journal of Pharmaceutical and Biomedical Analysis, 2012, 58,
58-64.
66. Ma H, Wang Y, Guo T, He Z, Chang X, Pu X. Simultaneous determination of
tetrahydropalmatine, protopine, and palmatine in rat plasma by LC-ESI-MS
and its application to a pharmacokinetic study. Journal of Pharmaceutical and
Biomedical Analysis, 2009, 49, 440–446.
67. Bai X, Qu J, Lu J, Kano Y, Yuan D. Pharmacokinetics of kakkalide and its
main metabolites in rat plasma determined by HPLC-DAD and LC–MS.
Journal of Chromatography B. 2011, 879, 395–402.
68. Kamble B, Gupta A, Patil D, Janrao S, Khatal L, Duraiswamy B. Quantitative
estimation of gymnemagenin in Gymnema sylvestre extract and its marketed
formulations using the HPLC–ESI–MS/MS method. 2012, Phytochemical
analysis, DOI: 10.1002/pca.2392.
69. Ding L, Huang X, Yang J, Bian X, Zhang Z, Liu G. Determination of
glycyrrhetic acid in human plasma by LC-ESI-MS. Journal of Pharmaceutical
and Biomedical. Anal, 2006, 40, 758–762.
70. John Lin Z, Qiu SX, Wufuer A, Shum L. Simultaneous determination of
glycyrrhizin, a marker component in Radix glycyrrhizae, and its major
metabolite glycyrrhetic acid in human plasma by LC-MS/MS. Journal of
Chromatography B, 2005, 814, 201-207.
71. Gelpi E. Biomedical and biochemical applications of liquid chromatography-
mass spectrometry. Journal of Chromatography A, 1995, 703, 59-80.
72. Capek M, Jirásko R, Lísa M. Recent developments in liquid chromatography
mass-spectrometry and related techniques. Journal of Chromatography A,
2012, 1259, 3–15.
Bibliography
180 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
73. Prasad B, Garg A, Takwani H, Singh S. Metabolite identification by liquid
chromatography mass spectrometry. Trends in Analytical Chemistry, 2011, 30
(2), 360-387.
74. Calixto JB. Efficacy, safety, quality control, marketing and regulatory
guidelines for herbal medicines (phytotherapeutic agents) The medicinal use
of herbal drugs. Brazilian Journal of Medical and Biological Research, 2000,
33, 179-189.
75. De Smet PA, Brauwers JR. Pharmacokinetic evaluation of herbal remedies
basic introduction, applicability, current status and regulatory needs. Clinical
Pharmacokinetics, 1997, 32, 427–436.
76. Handa SS, Kakul MK. “Medicinal plants –priorities in Indian medicines
diverse studies and implications,” in supplement to cultivation and utilization
of medicinal plants, 1996, 33–51, Regional Research Laboratories, Jammu
Tawi,India.
77. Mills S, Bone K. Principles and Practice of Phytotherapy, Churchill
Livingstone, Edinburgh, UK, 2000.
78. Agrosi M, Mischiatti S, Harrasser PC, Savio D. Oral bioavailablity of active
principals from herbal products in humans. A study on Hypericum perforatum
extracts using the soft gelatin capsule technology. Phytomedicine, 2000, 7 (6),
455-462.
79. Staffeldt B, Kerb R, Brockmoller J, Ploch M, Roots I. Pharmacokinetics of
hypericin and pseudohypericin after oral intake of the Hypericum perforatum
extract LI 160 in healthy volunteers. Journal of Geriatric Psychiatry and
Neurology, 1994, 7, 47-53.
80. Biber A, Fischer H, Romer A, Chatterjee SS. Oral bioavailability of
hyperforin from Hypericum extracts in rats and human volunteers.
Pharmacopsyciatry, 1998, 31, 36-43.
81. Schubert SY, Lansky EP, Neeman I. Antioxidant and eicosanoid enzyme
inhibition properties of Pomgranate seed oil and fermented juice flavonoids.
Journal of Ethnopharmacology, 1999, 66 (1), 11-17.
82. Doyle B, Griffiths LA. The metabolism of ellagic acid in the rat. Xenobiotica,
1980, 10, 247.
Bibliography
181 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
83. Lei F, Xing DM, LanXiang ,Yu-NanZhao,WeiWang ,Lu-JunZhang, Li-JunDu,
Pharmacokinetic study of ellagic acid in rat after oral administration of
pomegranate leaf extract. Journal of Chromatography B, 2003, 796, 189–194.
84. Sharma S, Hawaii V, Hingorani L, Shrivastava M, Bhate VR, Khiyani R.
Pharmacokinetic study of 11- Keto β-Boswellic Acid. Phytomedeicine, 2004,
11, 255-260.
85. Panossian A, Hovhannisyan A, Mamikonyan G, Abrahamian H,
Hambardzumyan E, Cabrielianl E, Goukasova G, Wikman G, Wagner H.
Pharmacokinetic and oral bioavailability of andrographolide from
Andrographis paniculata fixed combination Kan Jang in rats and human.
Phytomedicine, 2000, 7 (5), 351-364.
86. Baoqi W, Zhigong P, Congying W. Study on pharmacokinetic parameters of
andrographolide in rabbit plasma by chemiluminescence. Shenyang Yaoke
Daxue Xuebao, 1995, 12 (l), 5- 9.
87. Jayeul L, Euiju L, Donghyun K, Junhee L, Junghee Y, Byunghee K,
Studies on absorption, distribution and metabolism of ginseng in humans after
oral administration. Journal of Ethnopharmacology, 2009, 122, 143–148.
88. Fujisawa K, Tandon BN. Therapeutic approach to the chronic active
liver disease: Summary of a satellite symposium. In: Nishioka K, Suzuki
H, Mishiro S, Oda T,eds. Viral Hepatitis and Liver Disease. Tokyo:
Springer-Verlag, 1994, 662-665.
89. Akao T, Akao T, Hattori M, Kanaoka M K, Yamamoto T, Kobashi NK.
Hydrolysis of glycyrrhizin to 18 beta-glycyrrhetyl monoglucuronide by
lysosomal beta-D glucuronidase of animal livers. Biochemical Pharmacology,
1991, 41, 1025-1029.
90. Hattori M, Sakamoto T, Yamagishi T, Sakamoto K, Konishi K, Kobashi K.
N. Metabolism of glycyrrhizin by human intestinal flora.II. Isolation and
characterization of human intestinal bacteria capable of metabolizing
glycyrrhizin and related compounds. Chemical & Pharmaceutical Bulletin
1985, 33, 210-217.
91. Vibha JB, Choudhary K, Singh M, Rathore MS, Shekhawat NS, A Study on
pharmacokinetics and therapeutic efficacy of Glycyrrhiza glabra: A miracle
medicinal herb. Botany Research International, 2009, 2 (3), 157-163.
Bibliography
182 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
92. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin:
preclinical and clinical studies. Anticancer Research, 2003, 23, 363-98.
93. Limtrakul P, Lipigorngoson S, Namwong O, Apisariyakul A, Dunn FW.
Inhibitory effect of dietary curcumin on skin carcinogenesis in mice. Cancer
Letters, 1997, 116, 197–203.
94. Rao CV, Rivenson A, Simi B, Reddy BS. Chemoprevention of colon
carcinogenesis by dietary curcumin, a naturally occurring plant phenolic
compound. Cancer Research, 1995, 55, 259-66.
95. Kiso Y, Suzuki Y, Watanabe N, Oshima Y, Hikino H. Antihepatotoxic
principles of Curcuma longa rhizomes. Planta Medica, 1983, 49, 185-7.
96. Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of
curcumin (1, 7-bis- (4- hydroxy-3- methoxyphenyl)-1,6-heptadiene-3,5-dione)
in the rat. Xenobiotica, 1978, 8,761-8.
97. Wahlstrom B, Blennow G.A. study on the fate of curcumin in the rat. Acta
Pharmacologica et Toxicologica (Copenh), 1978, 43, 86-92.
98. Goel A, Kunnumakkara AB, Agarwal BB. Curcumin as ‘Curecumin’ From
kitchen to clinic. Biochemical Pharmacology, 2008, 75, 787–809.
99. Hussain K, Ismail Z, Sadikun A, Ibrahim P. Bioactive markers based
pharmacokinetic evaluation of extracts of a traditional medicinal plant, Piper
sarmentosum. Evidence-Based Complementary and Alternative Medicine,
2011, 1-7. doi:10.1093/ecam/nep143.
100. Kyung-Mi J, Lee JH, Jeon HY, Park CW, Honga DK, Jeong HJ, Lee SJ, Lee
SY, Lim KM. Pharmacokinetic study of ginsenoside Re with pure ginsenoside
Re and ginseng berry extracts in mouse using ultra performance liquid
chromatography /mass spectrometric method. Journal of Pharmaceutical and
Biomedical Analysis, 2010, 51, 278–283.
101. Chen LC, Lee MH, Chou MH, Lin, MF, Yang LL. Pharmacokinetic study of
paeoniflorin in mice after oral administration of Paeoniae radix extract.
Journal of Chromatography B, 1999, 735, 33–40.
102. Suryawanshi SR, Asthana K, Gupta RC. Simultaneous estimation of
mangiferin and four secoiridoid glycosides in rat plasma using liquid
chromatography tandem masss pectrometry and its application to
pharmacokinetic study of herbal preparation. Journal of Chromatography B,
2007, 858, 211–219.
Bibliography
183 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
103. Lee JH, Kim JM, Kim C. Pharmacokinetic analysis of rhein in Rheum
undulatum L. Journal of Ethnopharmacology, 2003, 84, 5-9.
104. Hua X, Fu YJ, Zu YG, Zhang L, Wang W, Luo M. Determination of
pinostrobin in rat plasma by LC–MS/MS: Application to pharmacokinetics.
Journal of Pharmaceutical and Biomedical Analysis, 2011, 56, 841–845.
105. Tanga L, Gonga Y, Lva C, Yea L, Liua L, Liua Z. Pharmacokinetics
of aconitine as the targeted marker of Fuzi (Aconitum carmichaeli) following
single and multiple oral administrations of Fuzi extracts in rat by
UPLC/MS/MS. Ethnopharmacology, 2011, doi:10.1016/j.jep.2011.08.070.
106. Juan P, Zengfeng S, Chen MA. Emodin studies on pharmacokinetics and
distribution in rat liver after Polygonum cuspidatum sieb. et Zucc. extract
administration. world science and technology. Modernisation of traditional
chinese medicine and Materia Medica, 2008, 10(1), 64-67.
107. Xie J, Ding C, Ge Q, Zhou Z, Zhi X. Simultaneous determination of
ginkgolides A, B, C and bilobalide in plasma by LC–MS/MS and its
application to the pharmacokinetic Study of Ginkgo biloba extract in rats.
Journal of Chromatography B, 2008, 864, 87–94.
108. Peng SW, Shen P, Lee L, Li J, Yong EL. Pharmacokinetics of
prenylflavonoids and correlations with the dynamics of estrogen action in sera
following ingestion of a standardized epimedium extract. Journal of
Pharmaceutical and Biomedical Analysis, 2009, 50, 216–223.
109. Saraf AS. Applications of novel drug delivery system for herbal
formulations. Fitoterapia, 2010, 81(7), 680-689.
110. Iosio T, Voinovich D, Perissutti B, Serdoz F, Hasa D, Grabnar I, Zara G.P,
Muntoni E, Pinto J.F,. Acqua S D. Oral bioavailability of silymarin
phytocomplex formulated as self-emulsifying pellets. Phytomedicine,
2011,18(6), 433-538.
111. Chen Y, Lin X, Park H, Greever R. Study of artemisinin nanocapsules as
anticancer drug delivery systems. Nanomedicine: Nanotechnology, Biology,
and Medicine, 2009, 5, 316–322.
112. Khandavilli S, Panchagnula R. Nanoemulsions as Versatile Formulations for
Paclitaxel Delivery: Peroral and Dermal Delivery Studies in Rats. Journal of
Investigative Dermatology, 2007, 127, 154–162.
Bibliography
184 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
113. Mohanty CS, Sahoo K. The in vitro stability and in vivo pharmacokinetics of
curcumin prepared as an aqueous nanoparticulate formulation, Biomaterials,
2010, 31, 6597-6611.
114. Swapna M, Sibabarata M, Mukul kumar B. Evaluation of the in vivo activity
and toxicity of Amarogentin, an anti-leishmanial agent in both liposomes and
niosome forms. Journal of antimicrobial chemotherapy, 1999, 44, 791-794.
115. Kidd PM. Bioavailability and activity of phytosome complexes from
botanical polyphenols: The Silymarin, Curcumin, Green Tea, and Grape Seed
Extracts. Alternative Medicine Review, 2009, 14(3), 226-246.
116. Milane HA, Ubeaud G, Thierry F, Jung VL. Isolation of quercetin’s salts
and studies of their physicochemical properties and antioxidant relationships.
Bioorganic & Medicinal Chemistry, 2004, 12, 3627-3635.
117. Yallapu MM, Gupta BK, Jaggi M, Chauhan SC. Fabrication of curcumin
encapsulated PLGA nanoparticles for improved therapeutic effects in
metastatic cancer cells. Journal of Colloid and Interface Science, 2010, 351,
19–29.
118. Yongmei H, Fenglin Z, Na L, Yanhong Y, Kean L. Studies on a high
encapsulation of colchicine by a niosome system. International Journal of
Pharmaceutics, 2002, 244, 73-80.
119. Sanoj R, Muthunarayanan M, Muthuchelian K, Chennazhi KP , Shanti N,
Jayakumar R. Saponin-loaded chitosan nanoparticles and their cytotoxicity to
cancer cell lines in vitro. Carbohydrate Polymers, 2011, 84, 407-416.
120. Laura S, Antonella S, Mariateresa C, Francesco C, D'Arrigo M, Domenico
T, Rao F, R Giuseppe. Phytocomplexes from liquorice (Glycyrrhiza glabra
L.) leaves Chemical characterization and evaluation of their antioxidant, anti-
genotoxic and anti-inflammatory activity. Fitoterapia, 2011, 82, 546-556.
121. You J, Cui FD, Han X, Wang YS, Yang L, Yu YW, Li QP. Study of the
preparation of sustained-release microspheres containing zedoary turmeric oil
by the emulsion-solvent-diffusion method and evaluation of the self-
emulsification and bioavailability of the oil. Colloids Surface B Biointerfaces,
2006, 48(1), 35-41.
122. Zheng Y, Hou SX, Chen T, Lu Y. Preparation and characterization of
transfersomes of three drugs in vitro. China Journal of Chinese Materia
Medica, 2006, 31(9), 728-31.
Bibliography
185 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
123. Zhaowu Z, Xiaoli W, Yangde Z, Nianfeng L. Preparation of matrine
ethosome, its percutaneous permeation in vitro and anti-inflammatory activity
in vivo in rats. Journal of Liposome Research, 2009, 19(2),155-62.
124. Cristiano C. Herbal interactions on absorption of drugs: Mechanisms of
action and clinical risk assessment. Pharmacological Research, 2010, 62, 207-
227.
125. (a) Gardiner P, Graham RE, Legedza AT, Eisenberg DM, Phillips RS.
Factors associated with dietary supplement use among prescription medication
users. Archives of Internal Medicine, 2006, 166, 1968-74.
(b) Abebe W. Herbal medication: potential for adverse interactions with
analgesic drugs. Journal of Clinical and Pharmaceutical Therapeutics, 2002,
27, 391–401.
126. Diamond BJ, Shiflett SC, Feiwel N, Matheis RJ, Noskin O, Richards JA,
Schoenberger NE. Ginkgo biloba extract: mechanisms and clinical indications.
Archives of Physical Medicine and Rehabilitation, 2000, 81, 668-67.
127. Zhang XY, Zhou DF, Su JM, Zhang PY. The effect of extract of Ginkgo
biloba added to haloperidol on superoxide dismutase in inpatients with chronic
schizophrenia. Journal of Clinical Psychopharmacology, 2001, 21, 85-88.
128. Zhang XY, Zhou D.F., Su J.M., Zhang P.Y. The effect of extract of Ginkgo
biloba added to haloperidol on superoxide dismutase in inpatients with chronic
schizophrenia. Journal of Clinical Psychopharmacology, 2001, 21, 85-88.
129. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed
drugs: a systematic review. Drugs, 2001, 61, 2163-2175.
130. Aslam M, Stockley IH. Interaction between curry ingredient (karela) and
drug (chlorpropamide). Lancet, 1979, 1, 607.
131. Yue QY, Bergquist C, Gerden B. Safety of St John's wort (Hypericum
perforatum). Lancet, 2000, 355, 576-577.
132. Ernst E. Second thoughts about safety of St John's wort. Lancet, 1999, 354,
2014-2016.
133. Singh YN. Kava: an overview. Journal of Ethnopharmacology, 1992, 37,
13-45.
134. Schelosky L, Raffauf C, Jendroska K, Poewe W. Kava and dopamine
antagonism. Journal of Neurology Neurosurgery & Psychiatry, 1995, 58, 639-
640.
Bibliography
186 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
135. Kuhn MA. 2002. Herbal remedies: drug-herb interactions. Critical Care
Nurse, 2002, 22, 22-28.
136. Kuhn M, Winston D. Herbal Therapy and Supplements: A Scientific and
Traditional Approach. Philadelphia, Pa: 2001, JB Lippincott.
137. Smith M. Drug interactions with natural health products/dietary
supplements: a survival guide. Paper presented at: Complementary and
Alternative Medicine: Implications for Clinical Practice and State-of-the-
Science Symposia; Boston, 2000, Mass.
138. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I.
Pharmacokinetic interaction of digoxin with an herbal extract from St John's
wort (Hypericum perforatum). Clinical Pharmacology & Therapeutics, 1999,
66, 338-345.
139. Sikka R, Magauran B, Ulrich A, Shannon M. 2005. Bench to bedside:
Pharmacogenomics, adverse drug interactions, and the cytochrome P450
system. Academic Emergency Medicine, 2005, 12, 1227-1235.
140. Sorensen JM. Herb-drug, food-drug, nutrient-drug, and drug-drug
interactions: mechanisms involved and their medical implications. Journal of
Alternative and Complementary Medicine, 2002, 8, 293-308.
141. Estabrook RW. The remarkable P450s: a historical overview of these
versatile hemeprotein catalysts. The Journal of the Federation of American
Societies for Experimental Biology, 1996, 10, 202-204.
142. Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, Duan W, Koh HL,
Zhou S. Herb-drug interactions: a literature review. Drugs, 2005, 65, 1239-
1282.
143. Karliova M, Treichel U, Malago M, Frilling A, Gerken G, Broelsch CE.
Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A
metabolism in a patient after liver transplantation. Journal Hepatology, 2000,
33, 853-855.
144. Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. Drug
interaction between St. John's wort and cyclosporine. Annals of
Pharmacotherapy. 2000, 34, 1013-1016.
145. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart
transplant rejection due to St John's wort. Lancet, 2000, 355, 548-549.
Bibliography
187 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
146. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction
between St. John's wort and theophylline. Annals of Pharmacotherapy, 1999,
33, 502.
147. Hiwale AR, Dhuley JN, Naik SR. Effect of co-administration of piperine
on pharmacokinetics of beta-lactam antibiotics in rats. Indian Journal of
Experimental Biology, 2002, 40, 277- 281.
148. Gupta SK, Bansal P, Bhardwaj RK, Velpandian T. Comparative anti-
nociceptive, anti-inflammatory and toxicity profile of nimesulide vs
nimesulide and piperine combination. Pharmacology Research, 2000, 41, 657-
662.
149. Mujumdar AM, Dhuley JN, Deshmukh VK, Raman PH, Thorat SL, Naik
SR. Effect of piperine on pentobarbitone induced hypnosis in rats. Indian
Journal of Experimental Biology, 1990, 28, 486-487.
150. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence
of piperine on the pharmacokinetics of curcumin in animals and human
volunteers. Planta Medica, 1998, 64, 353-356.
151. BanoG, Raina RK, Zutshi U, Bedi KL, Johri RK, Sharma SC. Effect of
piperine on bioavailability and pharmacokinetics of propranolol and
theophylline in healthy volunteers. European Journal of Clinical
Pharmacology, 1991, 41, 615-617.
152. Ching MS, Bichara N, Blake CL, Ghabrial H, Tukey RH, Smallwood RA.
Propranolol 4- and 5-hydroxylation and N-desisopropylation by cloned human
cytochrome P4501A1 and P4501A2. Drug Metabolism & Disposition, 1996,
24, 692-694.
153. Bano G, Raina RK, Zutshi U, Bedi KL, Johri RK, Sharma SC. Effect of
piperine on bioavailability and pharmacokinetics of propranolol and
theophylline in healthy volunteers. European Journal of Clinical
Pharmacology, 1991, 41, 615-617.
154. Tjia JF, Colbert J, Back DJ. Theophylline metabolism in human liver
microsomes: inhibition studies. Journal of Pharmacology and Experimental
Therapeutics, 1996, 276, 912-917.
155. Lin SP, Tsai SY, Hou YC, Chao PD. Glycyrrhizin and licorice significantly
affect the pharmacokinetics of methotrexate in rats. Journal of Agricultural
and Food Chemistry, 2009, 57, 1854-1859.
Bibliography
188 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
156. Chiang HM, Fang SH, Wen KC, Hsiu SL, Tsai SY, Hou YC, Chi YC, Chao
PD. Life-threatening interaction between the root extract of Pueraria lobata
and methotrexate in rats. Toxicology and Applied Pharmacology, 2005, 209,
263-268.
157. Angelo A. Herb–drug interactions: an overview of the clinical evidence.
Fundamental & Clinical Pharmacology, 2004, 19, 1–16
158. Ernst E. Possible interactions between synthetic and herbal medicinal
products. Part 1: a systematic review of the indirect evidence. Perfusion, 2000,
13, 2200–2211.
159. Keshavamurthy KR, Yoganarasimhan SN, "Flora of Coorg - Karnataka";
Vimsat publishers, Bangalore, 1990, 282.
160. Agnihotri AK, Khatoon S, Agarwal M, Rawat AS, Mehrota S, Pushpgandan
P. Pharmacognostical evaluation of Gymnema sylvestre R. Br. Natural
Products Science, 2004, 10(4), 168–172.
161. Madhurima SH, Ansari P, Alam S, Ahmad MS, Akhtar S. Pharmacognostic
and phytochemical analysis of Gymnema sylvestre R.Br. Leaves. Journal of
Herbal Medicine & Toxicology, 2009, 3 (1), 73-80.
162. Indian Medicinal Plants, A Compendium of 500 species, Orient Longman
Ltd., Madras. 1995, 3, 107-109.
163. Nadkarni KM. Indian Materia Medica , Popular prakashan, Bombay. 1993,
1,596-599.
164. Bhava prakash nigunta, Motilal banarsidas publications, 1998, 256.
165. Srikanth AV, Sayeeda M, Lakshmi NM, Ravi Kumar P , Madhava RB.
Anticancer Activity of Gymnema sylvestre R.Br. International Journal of
Pharmaceutical Sciences and Nanotechnology, 2010, 3(1), 897-899.
166. Khanna VG, Krishnan K, Glulia G. Leishmanicidal activity of saponins
isolated from the leaves of Eclipta prostrata and Gymnema sylvestre. Indian
Journal of Pharmacology, 2009, 41(1), 32-35.
167. Satdive RK, Abhilash P, Fulzele DP. Antimicrobial activity of Gymnema
sylvestre leaf extract. Fitoterapia, 2003, 74, 699-701.
168. Saneja A, Sharma C, Aneja KR, Pahwa R. Gymnema sylvestre (Gurmar): A
Review. Der Pharmacia Lettre, 2010, 2(1), 275-284.
Bibliography
189 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
169. Malik JK, Manvi FV, Alagawadi KR, Noolvi M. Evaluation of anti-
inflammatory activity of Gymnema sylvestre leaves extracts in rats.
International Journal of Green Pharmacy, 2008, 2(2), 114-15.
170. Warren RP, Warren RM, Weninger MG. "Inhibition of the sweet taste by
Gymnema sylvestre", Nature, 1969, 223, 94-95.
171. Gupta SS, Seth CB. “Experimental studies on pituitary diabetics Part II.
Comparison of blood sugar level in normal and anterior pituitary extract
induced hyperglycaemic rats treated with a few Ayurvedic remedies”, Indian
Journal of Medical Research, 1962, 50(5), 708 - 714.
172. Fushiki T, Kojima A, Imoto T, Inoue K, Sugimoto E, "Extract of Gymnema
sylvestre leaves and purified gymnemic acid inhibits glucose-stimulated
gastric inhibitory peptide secretion in rats", Journal of Nutrition, 1992, 122,
2367-2373.
173. Shanmugasundaram ERB, Gopinath KL, Shanmugasundaram KR,
Rajendran VM. “Possible regeneration of the islets of langerhans in
streptozotocin- diabetic rats given Gymnema sylvestre leaf extracts” Journal of
Ethnopharmacology, 1990, 30, 265-279.
174. Kuzuko Y, Kayoko A, Shigenoby A, Kouji M. “Structure studies of new
anitsweet constituents from Gymnema sylvestre”. Tetrahedron letters, 1989,
30(9),1130-1106.
175. Hong-Min I, Fumiyuki K, Yoshisuke T, “Isolation and Structure elucidation
of Gymnemic Acids, antisweet principles Gymnema sylvestre”, Chemical &
Pharmaceutical Bulletin, 1992, 40(6), 1366-1375.
176. Masayuki Y, Toshiyuki M, Masashi K, Yuhao L, Nubotoshi M, Johji Y,
Hisash M. “Medicinal Food stuffs (IX1) the inhibitors of glucose absorption
from the leaves of Gymnema sylvestre R.Br. (Asclepiadaceae): Structures of
Gymneomosides A and B” Chemical & Pharmaceutical Bulletin, 1997,
45(10),1671-1676.
177. Sahu NP, Mahato SB, Sarkar SK, Poddar G. Triterpenoid saponins from
Gymnema sylvestre. phytochemistry, 1996, 41(4), 1181-1185.
178. Davis SN. The role of glimepiride in the effective management of Type 2
diabetes. Journal of Diabetes and Its Complications, 2004, 18, 367–376.
179. Holstein A, Plaschke A, Egberts EH. Lower incidence of Severe
hypoglycaemia in patients with Type 2 diabetes treated with glimepiride
Bibliography
190 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
versus glibenclamide. Diabetes and Metabolism Research and Reviews, 2001,
17, 467–473.
180. Gregorio F, Ambrosi F, Cristallini S, Filipponi P, Santeusanio F. Effects of
glimepiride on insulin and glucagon release from isolated rat pancreas at
different glucose concentrations. Acta Diabetologica, 1996, 33, 25–29.
181. Riddle M, McDaniel P, Bugos C. First-dose C-peptide response and risk of
hypoglycemia are lower with glimepiride than glyburide(abstract). Diabetes
Care, 2001, 50(l2), A129.
182. PAR Glimepiride 1mg, 2mg , 3mg, 4mg & 6mg tablets PL 27583/0119-
0123, UK/H/1508/001-005/DC. Medicines and healthcare products regulatory
agency.
183. Eberhard D. Clinical profile of glimepiride. Diabetes Research and Clinical
Practice, 1995, 28, 139-146.
184. Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M.
Effect of CYP2C9 genetic polymorphisms on the efficacy and
pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes
Research and Clinical Practice, 2006, 72, 148–154.
185. Maged MY, Saleh NMWAFY, Protective potential of Glimepiride and
Nerium oleander extract on lipid profile, body growth rate, and renal function
in streptozotocin-induced diabetic rats. Turkish Journal of Biology, 2007, 31,
95-102.
186. Annonymus. Standards of medical care in diabetes. Diabetes Care, 2009,
32(1), 13-61.
187. Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR. The use
of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia,
2010, 53, 809-820.
188. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome:
systematic review and meta-analysis. British Medical Journal, 2003, 327, 951-
953.
189. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N.
Metformin in non-alcoholic steatohepatitis. Lancet, 2001, 358, 893-894.
190. Ibanez L, Ong K, Valls C, Marcos MV, Dunger DB, Zegher F. Metformin
treatment to prevent early puberty in girls with precocious pubarche. Journal
of Clinical Endocrinology & Metabolism, 2006, 91, 2888-2891.
Bibliography
191 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
191. Scheen, A.J. Clinical pharmacokinetics of metformin. Clinical
Pharmacokinetics, 1996, 30, 359-371.
192. Bristol-Myers Squibb. U.S. Food and Drug Administration. 2008.
Glucophage® (metformin hydrochloride tablets) Label Information.
193. Sirtori CR, Franceschini G, Galli-Kienle M, Cighetti G, Galli G., Bondioli
A, Conti F. Disposition of metformin (N,N-dimethylbiguanide) in man.
Clinical Pharmacology & Therapeutics, 1978, 24, 683-693.
194. Choi YH, Lee MG. Effects of enzyme inducers and inhibitors on the
pharmacokinetics of metformin in rats: involvement of CYP2C11, 2D1 and
3A1/2 for the metabolism of metformin. British Journal of Pharmacology,
2006, 149, 424-430.
195. Kimura N, Okuda M, Inui K. Metformin transport by renal basolateral
organic cation transporter hOCT2. Pharmacological Research, 2005, 22, 255-
259.
196. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of
metformin renal tubular secretion by cimetidine in man. British Journal of
Clinical Pharmacology, 1987, 23, 545-551.
197. Kudolo GB, Wang W, Javors M, Blodgett J. The effect of the ingestion of
Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in
non-diabetic and type 2 diabetic subjects-a double blind placebo-controlled,
crossover study. Clinical Nutrition, 2006, 25, 606-616.
198. Choi YH, Lee I, Lee MG. Effects of bacterial lipopolysaccharide on the
pharmacokinetics of metformin in rats. International Journal of Pharmacy,
2007, 337, 194-201.
199. Cho YK, Choi YH, Kim SH, Lee MG. Effects of Escherichia coli
lipopolysaccharide on the metformin pharmacokinetics in rats. Xenobiotica,
2009, 39, 946-954.
200. Michael UA, Uzuegbu BD, Okoye C ,Theophine F, Uzor P, Maxwell AO,
Benson VA. Antidiabetic effect of combined aqueous leaf extract of Vernonia
amygdalina and Metformin in rats. Journal of Basic and Clinical Pharmacy,
2010, 1(3), 197-202.
201. Kudolo GB, Wang W, Javors M, Blodgett J. The effect of the ingestion of
Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in
Bibliography
192 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
non-diabetic and type 2 diabetic subjects-a double blind placebo-controlled,
crossover study. Clinical Nutrition, 2006, 25, 606-616.
202. Choi YH, Lee I, Lee MG. Effects of bacterial lipopolysaccharide on the
pharmacokinetics of metformin in rats. International Journal of Pharmacy,
2007, 337, 194-201.
203. Cho YK, Choi YH, Kim SH, Lee MG. Effects of Escherichia coli
lipopolysaccharide on the metformin pharmacokinetics in rats. Xenobiotica,
2009, 39, 946-954.
204. Michael UA, Uzuegbu BD, Okoye C ,Theophine F, Uzor P, Maxwell AO,
Benson VA. Antidiabetic effect of combined aqueous leaf extract of Vernonia
amygdalina and Metformin in rats. Journal of Basic and Clinical Pharmacy,
2010, 1(3), 197-202.
205. Park JW, Choi KH. Acid- Base Equilibria and related properties of chitosan
Bulletin of Korean Chemical society, 1983, 4(2) 68-71.
206. Nair R, Reddy H, Ashok Kumar CK, Jayraj KK. Application of chitosan
microspheres as drug carriers : a review. Journal of Pharmaceutical Sciences
& Research, 2009, 1(2), 1-12.
207. Dasha M, Chiellini F , Ottenbriteb RM, Chiellini E. Chitosan—A versatile
semi-synthetic polymer in biomedical applications. Progress in Polymer
Science, 2011, 36, 981-1014.
208. Harish KV, Tharanathan RN. Chitin/chitosan:modifications and their
unlimited application Potential-an overview. Trends in Food Science &
Technology, 2007,18, 117-131.
209. Astete CE, Sabliov CM. Synthesis and characterization of PLGA
nanoparticles. Journal of Biomaterials Science - Polymer Edition, 2006, 17(3),
247–289.
210. Makadia HK, Siege SJ. Poly Lactic-co Glycolic Acid (PLGA) as
Biodegradable Controlled Drug Delivery Carrier. Polymers, 2011, 3, 1377-
1397.
211. Yang YY, Chung TS. Morphology, drug distribution, and in vitro release
profiles of Biodegradable polymeric microspheres containing protein
fabricated by double-emulsion solvent extraction/evaporation method.
Biomaterials, 2001, 22, 231–241.
Bibliography
193 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
212. Panagi Z, Beletsi A, Evangelatos G, Livaniou E, Ithakissios DS,
Avgoustakis K. Effect of dose on the biodistribution and pharmacokinetics of
PLGA and PLGA-mPEG nanoparticles. International Journal of Pharmacy,
2001, 221,143–152.
213. Bazile DV, Ropert C, Huve P, Verrecchia T, Marlard M, Frydman A,
Veillard M, Spenlehauer G. Body distribution of fully biodegradable [14C]
poly(lacticacid) nanoparticles coated with albumin after parenteral
administration to rats. Biomaterials, 1992, 13, 1093–1102.
214. ‘Gymnema sylvestre’ Master document, 1-20, developed by Quality Control
Dept Natural remedies Pvt Ltd. Bangalore, India.
215. ICH Q2B, Validation of analytical procedure: Methodology International
conference on hormonisation, Geneva, 1996, 1-11.
216. Sangster J. Octanol-water partition coefficients. Fundamentals of physical
chemistry, 1997, vol 2 Wiley series in solution chemistry. Chichester: John
Wiley & Sons Ltd.
217. OECD, Guideline for testing of chemicals, 423, 2001, 1-14.
218. Guidance for Industry: Bioanalytical Method Validation, USFDA. 2001, 1-
22. http://www.fda.gov/cder/guidance/index.htm.
219. Rejinold NS, Muthunarayanan M, Muthuchelian K, Chennazhi KP, Nair SV,
Jayakumar R. Saponin-loaded chitosan nanoparticles and their cytotoxicity to
cancer cell lines in vitro. Carbohydrate Polymers, 2011, 84, 407-416.
220. Gupta H, Mohammed A, Khar RK, Asgar A, Aseemn B, Mittal G.
Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery.
Nanomedicine: Nanotechnology, Biology, and Medicine, 2010, 6, 324-333.
221. Nagarwal RC, Kumar R, Pandit JK. Chitosan coated sodium alginate-
chitosan nanoparticles loaded with 5-FU for ocular delivery: In vitro
characterization and in vivo study in rabbit eye. European Journal of
Pharmaceutical Sciences, 2012, 47(4), 678-685.
222. Hadi AM, Genevi E, Thierry FV, Louis J. Isolation of quercetin’s salts and
studies of their physicochemical properties and antioxidant relationships.
Bioorganic & Medicinal Chemistry, 2004, 12, 3627-3635.
223. Strelow EWE, Toerien FVS, Weinert CHSW. Accurate determination of
traces of sodium and potassium in rocks by ion exchange followed by atomic
absorption spectroscopy. Analytica Chimica Acta, 1970, 50(3), 399-405.
Bibliography
194 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
224. Pitchai D, James E, Khanzan AMMF. A novel dihydroxy gymnemic
triacetate isolated from Gymnema sylvestre possessing normoglycemic and
hypolipidemic activity on STZ-induced diabetic rats. Journal of
Ethnopharmacology, 2009, 126, 339-344.
225. Sanjay P, Nirav G, Ashok S, Anand S. In vitro cytotoxicity activity of
Solanum nigrum extract against Hela cell line and vero cell line. International
Journal of Pharmacy and Pharmaceutical Sciences, 2009, 1,(1), 38-46.
226. Elena C, Marisela T, Jianni X, Sucha S, Dale EJ. Interactions between
traditional Chinese medicines and Western therapeutics. Current Opinion in
Drug Discovery & Development, 2010, 13(1), 50-65.
227. Laura G, Esther S, Maria JO, Cristina V, Cinta B, Mique M, Mayte B, Anna
A, Santiago GV, Gerard P. Identification of Novel human dipeptidyl
peptidase-IV inhibitors of natural origin (PartII): in silico prediction
antidiabetic extracts. PLoSONE, 2012, 7(9), 1-7.
228. Vague P, Coste TC, Jannot MF, Raccah D, Tsimaratos M. C-peptide, Na+,
K+-ATPase, and Diabetes. Experimental Diabetes.Research, 2004, 5, 37–50.
229. Catherine K, Fabrice B, Kiriaki P, Vassilis D, Philippe C. Evaluation of
aldose reductase inhibition and docking studies of 6’-nitro and 6’,6”-
dinitrorosmarinic acids. European Journal of Medicinal Chemistry, 2010, 45,
1663–1666.
230. Lala LG, D’Mello PM, Naik SR. Pharmacokinetic and pharmacodynamic
studies on interaction of “Trikatu” with diclofenac sodium. Journal of
Ethnopharmacology, 2004, 91, 277–280.
231. Fakeye TO, Oladipupo T, Showande O, Ogunremi Y. Effects of Co-
administration of extract of Carica papaya Linn (family Cariaceae) on activity
of two oral hypoglycemic agents. Tropical Journal of Pharmaceutical
Research, 2007, 6(1), 671-678.
232. Kyung-Mi J, Ji-Hae L, Hee-Young J, Chan-Woong P, Deok-Ki H, Hye-Jin
J, Sang JL, Seok-Yong L, Kyung-Min L. Pharmacokinetic study of
ginsenoside Re with pure ginsenoside Re and ginseng berry extracts in mouse
using ultra performance liquid chromatography/mass spectrometric method.
Journal of Pharmaceutical and Biomedical Analysis, 2010, 51, 278–283.
233. Warude D, Patwardhan B. Botanicals: quality and regulatory issues. Journal
of Scientific and Industrial Research, 2005, 64: 83-92.
Bibliography
195 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
234. World Health Organization, Quality control methods for medicinal plant
materials - Revised Draft Update, 1998, 1-49.
235. Patil D, Gautam M, Mishra S, Jadhav U, Suresh K, Gairola S, Jadhav SS,
Patwardhan B. Physicochemical stability and biological activity of Withania
somnifera extract on real time and accelerated storage conditions. Planta
Medica, 2010, 76, 481-488.
236. Chitalange SS, Kulkarni PS, Patil DL, Patwardhan B, Nanda RK. High
performance liquid chromatographic fingerprint for quality control of
Terminalia arjuna containing Ayurvedic churna formulations. Journal of the
Association of Official Analytical Chemists, 2009, 92, 1016-20.
237. Patel K, Gadewar M, Tripathi R, Patel DK.. Pharmacological and analytical
aspects of gymnemic acid: a concise report. Asian Pacific Journal of Tropical
Disease, 2012, 414-416.
238. Yoshikaua K, Alimotoa K, Ariharaa S, Natsuura K. Structure studies of new
antisweet constituents from Gymnema sylvestre. Tetrahedron Letters, 1989,
30, 1103-1106.
239. Trivedi PD, Pundarikakshudu K, Shah KA. Validated reverse phase liquid
chromatographic method for quantification of gymnemagenin in the Gymnema
sylvestre R. Br. leaf samples, extract and market formulation. International
Journal of Applied Sciences and Engineering, 2011, 9, 25-31.
240. Toshiaki I, Yamamoto FM, Akiko M, Hiroyuki H. High-performance liquid
chromatography-atmospheric pressure ionization mass spectrometry of
gymnemic acids. Journal of Chromatography, 1991, 557, 383-389.
241. Toshihiro Y, Kenzi M, Kenzo O, Osamu T. Quantitative analysis of
gymnemic acids by high performance liquid chromatography. Nippon
Shokuhin Kagaku Kaishi, 1994, 41, 202- 205.
242. Valivarthi SRR, Kannababu S, Gottumukkala VS. Standardisation of
Gymnema sylvestre R.Br. by high-performance thin-layer chromatography: an
improved method. Phytochemical Analysis, 2006, 17, 192-196.
243. Hamed A, I, Janda B, Mahalel UA, Stochmal A, Oleszek W. Profiles of
steroidal saponins from the aerial parts of Tribulus pentandrus, T.
megistopterus sub sp. pterocarpus and T. parvispinus by LC–ESI–MS/MS.
Q11. Phytochemical Analasis, 2012, DOI: 10.1002/pca.2363.
Bibliography
196 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
244. Patil D, Gautam M, Mishra S, Jadhav U, Suresh K, Gairola S, Jadhav S.S,
Patwardhan B. Physicochemical stability and biological activity of Withania
somnifera extract on real time and accelerated storage conditions. Planta
Medica, 2010, 76, 481-488.
245. Patil D, Mishra S, Gautam M, Kulkarni P, Suresh K, Gairola S, Jadhav SS,
Patwardhan B. Estimation of protoberberine alkaloids in Tinospora cordifolia
stem crude powder, processed extracts and marketed formulations using
HPLC-DAD method. Chromatographia, 2010, 71, 341-345.
246. Valivarthi SRR, Kannababu S, Gottumukkala VS. Standardisation of
Gymnema sylvestre R.Br. by high-performance thin-layer chromatography: an
improved method. Phytochemical Analasis, 2006, 17, 192-196.
247. Yumiko N, Yukari T, Yasuhide T, Tadashi S. Fecal steroid excretion is
increased in rats by oral administration of gymnemic acids contained in
Gymnema sylvestre leaves. Journal of Nutrition, 1999, 129, 1214–1222.
248. Chattopadhyay RR. Possible mechanism of antihyperglycemic effect of
Gymnema sylvestre leaf extract, Part I. General Pharmacology, 1998, 31(3),
495-496.
249. Reinhold H, Nordman CE. The Crystal Structure of the Triterpene
Gymnemagenin, C30H5oO6. Acta Crystalographica, 1974, B30, 1435.
250. SubbaRao G, Sinsheimer JE. Constituents from Gymnema sylvestre Leaves
VIII: Isolation, Chemistry, and Derivatives of Gymnemagenin and
Gymnestrogenin. Journal of Pharmaceutical Sciences, 1971, 60(2), 190-192.
251. Persaud SJ, Al-Majed H, Raman A and Jones PM. Gymnema sylvestre
stimulates insulin release in vitro by increased membrane permeability.
Journal of Endocrinology, 1999, 163, 207-212.
252. Trivedi PD, Pundarikakshudu K. Isolation of gymnemagenin and
development and comparision of the validated HPLC and HPTLC methods for
estimation of gymnemagenin from plant leaves, market extract and
formulation. American Association of Pharmaceutical Sciences Abstract,
2009.
253. Elusiyan CA, Msagati TAM, Shode FO, Mamba BB. Measurements of
distribution coefficients and lipophilicity values for oleanolic acid and
betulinic acid extracted from indigenous plants by hollow fibre supported
Bibliography
197 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
liquid membrane. Bulletin of Chemical Society Ethiopia, 2011, 25(3), 321-
332.
254. Guidance for Industry: Bioanalytical Method Validation, United States Food
Drug & Administration (USFDA), 2001.
255. Lavie D, Glotter E, Shvo Y. Constituents of Withania somnifera Dun. Part
IV. The structure of withaferin A. Journal of American Chemical Society,
1965, 30, 7517-7531.
256. Gopinath R, Naidu RAS. Pharmaceutical Preformulation Studies – Current
Review International Journal of Pharmaceutical & Biological Archives, 2011,
2(5), 1391-1400.
257. Pakkir Mohamed SA, Janakiraman K. A review of on preformulation studies
of drugs. International Journal of Pharmaceutical Research and Development,
2012, 4(5), 64-74.
258. Indian Pharmacopoeia, Indian Pharmacopoeia commission, Ghaziabad, 2007
259. Santanu M, Mahendra DK, Vipin S. Studies on physical chemical
compatibility between synthetic and herbal drugs with various pharmaceutical
excipients. Der Pharmacia Lettre, 2011, 3(5), 173-178.
260. Pan Y, Zheng JM, Zhao HY, Li YJ, Xu H, Wei G. Relationship between
drug effects and particle size of insulin-loaded bioadhesive microspheres.
Acta Pharmacologica Sinica, 2002, 23(11),1051-1056.
261. Hui L, Changyou G. Preparation and properties of ionically cross-linked
chitosan nanoparticles. Polymers for Advanced Technologies, 2009, 20, 613-
619.
262. Jigar L, Mohan R, Manisha L, Ambikanandan M. Protein functionalized
tramadol-loaded PLGA nanoparticles preparation, optimization, stability and
pharmacodynamic studies. Drug Development and Industrial Pharmacy, 2012,
1–11.
263. Jose MB, Mariko M, Kozo T, Tsuneji N. Encapsulation of Hydrophilic and
Lipophilic Drugs in PLGA Nanoparticles by the Nanoprecipitation Method.
Drug Development and Industrial Pharmacy, 1999, 25(4), 471-476.
264. Murali MY, Gupta BK, Jaggi M, Chauhan SC. Fabrication of curcumin
encapsulated PLGA nanoparticles for improved therapeutic effects in
metastatic cancer cells. Journal of Colloid and Interface Science, 2010, 351,
19-29.
Bibliography
198 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
265. El-Sherbiny IM, Abdel-Mogib M, Dawidar AM. Biodegradable pH-
responsive alginate-poly (lactic-coglycolic acid) nano/micro hydrogel
matrices for oral delivery of silymarin. Carbohydrate Polymers, 2011, 83,
1345-1354.
266. Liu Z, Li J, Zeng Z, Liu M, Wang M. The antidiabetic effects of cysteinyl
metformin, a newly synthesized agent, in alloxan- and streptozocin-induced
diabetic rats. Chemico-Biological Interactions, 2008, 173, 68-75.
267. Kameswararao B, Kesavulu MM, Apparao C. Evaluation of antidiabetic
effect of Momordica cymbalaria fruit in alloxan-diabetic rats. Fitoterapia,
2003, 74, 7-13.
268. Khanna VG, Kannabiran K. Anticancer-cytotoxicity activity of saponins
isolated from the leaves of G. sylvestre and E. prostrata on HeLa cells.
International journal on Green Pharmacy, 2009, 227-229.
269. Laura G, Esther S, Maria JO, Cristina V, Cinta B, Miquel M, Mayte B, Anna
A, Santiago GV, Gerard P. Identification of Novel Human Dipeptidyl
Peptidase-IV Inhibitors of Natural Origin (PartII): In Silico Prediction in
Antidiabetic Extracts. PLoSONE. 2012, (9), doi:10.1371/journal.pone.
0044972.
270. Shrikanth HH, Manojit P. Medicinal chemistry approaches to the inhibition
of dipeptidylpeptidase-4 for the treatment of type 2 diabetes. Bioorganic &
Medicinal Chemistry, 2009, 17, 1783-1802.
271. Sutton JM, Clark DE, Dunsdon SJ, Fenton G, Fillmore A, Higgs C, Hurley
CA, Krintel SL, MacKenzie RE, Duttaroy A, Maniara W, Sedrani R, Namoto
K, Ostermann N, Gerhartz B, Trappe J, Hassiepen U, Baeschlin DK, Harris
NV, Gangl E, Sirockin F. Novel heterocyclic DPP-4 inhibitors for the
treatment of type 2 diabetes. Bioorganic & Medicinal Chemistry Letters,
2012, 22, 1464-1468.
272. Kaelin DE, Leiting B, Petrov A, Smenton AL, Lyons KA, Scapin G,
Weber AE, Eiermann GJ, Patel RA, Wu JK, Duffy JL, Huaibing H, Patel SB,
Thornberry NA. 4-Arylcyclohexylalanine analogs as potent, selective, and
orally active inhibitors of dipeptidyl peptidase IV. Bioorganic & Medicinal
Chemistry Letters, 2007, 17, 5806-5811.
273. Cheon HG, Sun-Mee K, Sung-Don Y, Jae DH, Joong-Kwon C. Discovery of
a novel protein tyrosine phosphatase-1B inhibitor, KR61639:potential
Bibliography
199 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
development as an antihyperglycemic agent. European Journal of
Pharmacology, 2004, 485, 333-339.
274. Ramírez-Espinosa JJ, Rios MY, Lopez-Martínez S, Lopez-Vallejo F,
Medina-Franco JL, Paoli P, Camici G, Navarrete-Vázquez G, Ortiz-Andrade
R, Estrada-Soto. Antidiabetic activity of some pentacyclic acid triterpenoids,
role of PTPe1B: In vitro, in silico, and in vivo approaches. European Journal
of Medicinal Chemistry, 2011, 46, 2243-2251.
275. Alice YYC, Fantus IG. Oral antihyperglycemic therapy for type 2 Diabetes
Mellitus. Canadian medical Association Journal, 2005, 172, 2, 213-226.
276. Kochi RB, Desaiah D, Cutkomp LK. Inhibition of ATPases by Gymnemic
acids. Chemico-Biological Interactions., 1973, 7, 121-125.
277. Ribalet B, Mirell CJ, Johnson DG, Levin SR. Sulfonylurea Binding to a
Low-affinity Site inhibits the Na/K-ATPase and the KATP Channel in Insulin-
secreting Cells. Journal of General Physiology, 1996, 107, 231-241.
278. Shimizu K, Iino A, Nakajima J, Tanaka K, Nakajyo S, Urakawa N, Atsuchi
M, Wada T, Yamashita C. Suppression of glucose absorption by some
fractions extracted from Gymnema sylvestre leaves. Journal of Veterinary
Medical Science, 1997, 59(4), 245-251.
279. Ogawa H, Shinoda T, Cornelius F, Toyoshima C. Crystal structure of the
sodium-potassium pump (Na+K+-ATPase) with bound potassium and
ouabain. Proceedings of National Acadamy of Sciences USA, 2009, 106,
13742-13747.
280. Urzhumtsev A, Tête-Favier F, Mitschler A, Barbanton J, Barth P,
Urzhumtseva L, Biellmann JF, Podjarny AD, Moras D. A „specificity‟
pocket inferred from the crystal structures of the complexes of aldose
reductase with the pharmaceutically important inhibitors tolrestat and sorbinil.
Structure, 1997, 5, 601-612.
281. Han-Cheng Z, Hong Y, Conway BR, Derian CK, Addo MF, Gee-Hong K,
Hecker LR, Croll DR, Jian L, Westover L, Jun ZX, Look R, Demarest KT,
Andrade-Gordon P, Damiano BP, Maryanoff BE. 3-(7-Azaindolyl)-4-
arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3.
Bioorganic & Medicinal Chemistry Letters, 2004, 14, 3245-3250.
282. Qing Y, Guiqing X, Dan L, Zhe C, Jia L, Yongzhou H. Synthesis and
biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen
Bibliography
200 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
synthase kinase-3b (GSK-3b) inhibitors. Bioorganic & Medicinal Chemistry,
2009, 17, 4302-4312.
283. Lagishetty C, Rajareddy K, Arumugam K, Bala TS, Srirangam R, Ramesh
M, Nuggehally RS. A rapid and highly sensitive method for the determination
of glimepiride in human plasma by liquid chromatography–electrospray
ionization tandem mass spectrometry: application to a pre-clinical
pharmacokinetic study. Biomedical Chromatography, 2008, 22, 58–63.
284. Yomiko N, Yukari T, Yasuhide T, Tadashi S. Fecal steroid excretion is
increased in rats by oral administration of Gymnemic acids contained in
Gymnema sylvestre leaves. Journal of Nutrition, 1999, 129, 1214-222.
285. Trivedi PD, Pundarikakshudu K, Shah KA. Validated reverse phase liquid
chromatographic method for quantification of gymnemagenin in the Gymnema
sylvestre R. Br. leaf samples, extract and market formulation. International
Journal of Applied Science and Engineering, 2011, 9, 25-31.
286. Valivarthi SRR, Kannababu S, Gottumukkala VS. Standardisation of
Gymnema sylvestre R.Br. by high-performance thin-layer chromatography: an
improved method. Phytochemical Analysis, 2006, 17, 192-196.
287. Ching J, Lin HS, Tan CH, Koh HL. Quantification of α- and β-amyrin in rat
plasma by gas chromatography-mass spectrometry: application to preclinical
pharmacokinetic study. Journal of Mass Spectrometry, 2011, 46(5), 457-64.
288. Schrader E, Schwankl W, Sieder C, Christoffel V. Comparison of the
bioavailability of beta-aescin after single oral administration of two different
drug formulations containing an extract of horse-chestnut seeds. Pharmazie,
1995, 50(9), 623-7.
289. Vijayanand R, Aralelimath, Bhise SB. Anti-diabetic effects of Gymnema
sylvester extract On streptozotocin induced diabetic rats and possible β-cell
protective and regenerative evaluations. Digest Journal of Nanomaterials and
Biostructures, 2012, 7(1), 135–142.
290. Kamble B, Gupta A, Patil D, Khatal L, Janrao S, Ismail M, Duraiswamy B.
Determination of gymnemagenin in rat plasma using high performance liquid
chromatography-tandem mass spectrometry: Application to pharmacokinetics
after oral administration of Gymnema sylvestre extract. Biomedical
Chromatography, 2012, DOI 10.1002/bmc.2845.
Bibliography
201 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
291. Christensen LP. Ginsenosides chemistry, biosynthesis, analysis, and
potential health effects. Advances in Food and Nutrition Research, 2009, 55,
1-99.
292. Shakyaa S, Zhua H, Dinga L, Dua XL, Qia XM, Yang XL, Yang ZL.
Determination of asperosaponin VI in dog plasma by high-performance liquid
chromatography–tandem mass spectrometry and its application to a pilot
pharmacokinetic study. Biomedical Chromatography, 2012, 26, 109-114.
293. Hana WJ, Xiaa YF, Daib Y. Development and validation of high-
performance liquid chromatography/ electrospray ionization mass
spectrometry for assay of madecassoside in rat plasma and its application to
pharmacokinetic study. Biomedical Chromatography, 2012, 26, 26–32.
294. Cai F, Sun L, Gao S, Yanga Y, Yanga Q, Chena W. A rapid and sensitive
liquid chromatography–tandem mass spectrometric method for the
determination of timosaponin BII in blood plasma and a study of the
pharmacokinetics of saponin in the rat. Journal of Pharmaceutical and
Biomedical Analysis, 2008, 48, 1411-1416.
295. Alejandro DB, Martha SB. Genotoxicity of Streptozotocin. Mutation
Research, 2002, 512, 121-134.
296. Fernandes NP, Lagishetty CV, Panda VS, Naik SR. An experimental
evaluation of the antidiabetic and antilipidemic properties of a standardized
Momordica charantia fruit extract. BMC Complementary Alternative
Medicine, 2007, 7, 29.
297. Liu Z, Li J, Zeng Z, Liu M, Wang M. The antidiabetic effects of cysteinyl
metformin, a newly synthesized agent, in alloxan- and streptozocin-induced
diabetic rats. Chemico-Biological Interactions, 2008, 173, 68-75.
298. Kirpichnikov D, Mc Farlane SI, Sowers JR. Metformin: an update. Annals of
Internal Medicine, 2002, 137, 25-33.
299. Shanmugasundaram ER, Gopinath KL, Shanmugasundaram KR, Rojendran
VM. Possible regeneration of the islets of Langerhans in streptozotocin-
diabetic rats given Gymnema sylvestre leaf extracts. Journal of
Ethnopharmacology, 1990,30, 265-279.
300. Shanmugasundaram ER, Gopinath KL, Shanmugasundaram KR, Rojendran
VM. Possible regeneration of the islets of Langerhans in streptozotocin-
Bibliography
202 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
diabetic rats given Gymnema sylvestre leaf extracts. Journal of
Ethnopharmacology, 1990, 30, 265-279.
301. Shanmugasundaram KR, Panneerselvam C, Samudram P,
Shanmugasundaram ER. Enzyme changes and glucose utilisation in diabetic
rabbits: the effect of Gymnema sylvestre, R.Br. Journal of
Ethnopharmacology, 1983, 7, 205-234.
302. Bishayee A, Chatterjee M, "Hypolipidaemic and antiatherosclerotic effect of
oral Gymnema sylvestre R.Br. leaf extract in albino rats fed on a high fat diet".
Phytotherapy Research, 1994, 8(2), 118-120.
303. Reynolds RM. Corticosteroid-mediated programming and the pathogenesis
of obesity and diabetes. Journal of Steroid Biochemistry & Molecular Biology,
2010, 122, 3-9.
304. Ardilouze JL, Pierre M, Nicole GPCR, Carpentier AC, Langlois MF,
Baillargeon JP, Adrenocortical dysregulation as a major player in insulin
resistance and onset of obesity. American Journal of Physiology,
Endocrinology and Metabolism, 293:E1465-E1478, 2007, doi:
10.1152/ajpendo.00516.2007
305. Panneerselvam K, Kodukkur VP. Antihyperglycemic effect of 18ß-
glycyrrhetinic acid, aglycone of glycyrrhizin, on streptozotocin-diabetic rats.
European Journal of Pharmacology, 2009, 606, 269-273.
306. Ko BS, Jang JS, Hong SM, Sung SR, Lee JE, Lee MY, Jeon WK, Park S.
Changes in components, Glycyrrhizin and Glycyrrhitinic acid, in raw
Glycrrhiza uralensis fish, modify insulin sensitising and insulinotropic action.
Bioscience, Biotechnology and Biochemistry, 2007, 71(6), 1452-1461.
307. http://datasheets.scbt.com/sc-205573.pdf accessed on 15-11-2012
308. http://www.mdidea.com/products/herbextract/ursolicacid/data.html accessed
on 15-11-2012
309. B. Kauppi, C. Jakob, M. Farnegardh, J. Yang, H. Ahola, M. Alarcon, K.
Calles, O. Engstrom, J. Harlan, S. Muchmore, A. K. Ramqvist, S. Thorell, L.
Ohman, J. Greer, J. A. Gustafsson, J. C. Duke, M. Carlquist. The three
dimensional structures of antagonistic and agonistic forms of the
Glucocorticoid receptor ligand-binding domain. The Journal of Biological
Chemistry, 2003, 278(25), 22748-22754.
Bibliography
203 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
310. Link JT, Bryan S, Jyoti P, Marlena G, Annika GN, Jiahong W, Steven F,
Denise W, Brad Z, Phong N, Bach H, Schmidt JM, Sue S, Zhenping T,
Thomas JR, Gary R, Jia D, Benjamin L, Geldern TWV and Jacobson PB.
Antidiabetic Activity of Passive Nonsteroidal Glucocorticoid Receptor
Modulators. Journal of Medicinal Chemistry, 2005, 48, 5295-5304.
311. Chang HY, Wallis M, and Tiralongo E. Use of complementary and
alternative medicine among people living with diabetes: literature review.
Journal of Advanced Nursing, 2007, 58(4), 307–319.
312. Mehrotra R, Bajaj S, Kumar D. Use of complementary and alternative
medicine by patients with diabetes mellitus. National Medical Journal of
India, 2004, 17(5), 243-5.
313. Zhou S, Zhou W, Li C, Chen X, Yu X, Xue C, Herington A. Identification
of drugs that interacts with herbs in drug development. Drug Discovery Today,
2007, 12, 664-673.
314. Gardiner P, Phillips R, Shaughnessy AF. Herbal and dietary supplement-
drug interactions in patients with chronic illnesses. American Family
Physician, 2008, 77, 73-78.
315. Xu H, Williams KM, Liauw WS, Murray M, Day RO, McLachlan AJ.
Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and
pharmacodynamics of gliclazide. British Journal of Pharmacology, 2008,
153, 1579-1586.
316. Nishimura N, Naora K, Hirano H, Iwamoto K. Effects of Sho-saiko-to on
the pharmacokinetics and pharmacodynamics of tolbutamide in rats. Journal
of Pharmacy and Pharmacology, 1998, 50, 231-236.
317. Shanmugasundaram ER, Gopinath KL, Shanmugasundaram KR, Rojendran
VM. Possible regeneration of the islets of Langerhans in streptozotocin-
diabetic rats given Gymnema sylvestre leaf extracts. Journal of
Ethnopharmacology, 1990, 30, 265-279.
318. Shanmugasundaram KR, Panneerselvam C, Samudram P,
Shanmugasundaram ER. Enzyme changes and glucose utilisation in diabetic
rabbits: the effect of Gymnema sylvestre, R.Br. Journal of
Ethnopharmacology, 1983, 7, 205-234.
Bibliography
204 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001
319. Krauss H, Jacek K, Marian G, Premyslaw S, Kinga M, Jacek P, Janusz P.
The influence of glimepiride on the oxidative state of rats with streptozotocin-
induced hyperglycemia. Medical Science Monitor, 2003, 9, 389-393.
320. Haupt A, Kausch C, Dahl D, Bachmann O, Stumvoll M, Haring Hans-U,
Matthael S. Effect of Glimepiride on insulin stimulated glycogen synthesis in
cultured human skeleton muscle cells. A comparision to glibenclamide.
Diabetes care, 2002, 25, 2129-2132.
321. Krauss H, Jacek K, Marian G, Premyslaw S, Kinga M, Jacek P, Janusz P.
The influence of glimepiride on the oxidative state of rats with streptozotocin-
induced hyperglycemia. Medical Science Monitor, 2003, 9, 389-393.
322. Muller G, Satoh Y, Geisen K. Extrapancreatic effects of sulfonylureas-a
comparison between glimepiride and conventional sufonylureas. Diabetes
Research and Clinical Practice, 1995, S, 115-37.
323. Yamazoe Y, Murayama N, Shimada M, Yamauchi K, Kato R. Cytochrome
P450 in livers of diabetic rats: regulation by growth hormone and insulin.
Archives of Biochemistry and Biophysics, 1998, 268, 567-575.
324. Vega P, Gaule C, Mancilla J, Del Villar E. Comparison of alloxan and
streptozotocin induced diabetes in rats: differential effects on microsomal drug
metabolism. General Pharmacology, 1993, 24, 489-495.
325. Nawa A, Fujita-Hamabe W, Kishioka S, Tokuyama S. Decreased
expression of intestinal P-glycoprotein increases the analgesics effects of oral
morphine in a streptozotocin-induced diabetic mouse model. Drug Metabolism
and Pharmacokinetics., 2011, 26(6), 584-591.
.